SYNLAB AG · ISIN: DE000A2TSL71 · EQS - Company News

Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow

Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement, Cinven will acquire Elliott’s current direct minority stake of approximately 10% in SYNLAB. Elliott will become an indirect minority shareholder in S...

XETR:SYAB Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News SYNLAB AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (2)
Short Selling (DE) (1)
Short Selling (UK) (0)
30 October 2024 07:32AM
Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow
DE000A2TSL71
Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement,...
SYNLAB AG
About the publication
17 September 2024 04:00PM
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp
DE000A2TSL71
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp International private equity firm, Cinven, has reached an agreement to sell an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive la...
SYNLAB AG
About the publication
17 September 2024 04:00PM
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp
DE000A2TSL71
Cinven to sell minority stake in SYNLAB to strategic investor Labcorp International private equity firm, Cinven, has reached an agreement to sell an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive la...
SYNLAB AG
About the publication
04 June 2024 08:46PM
Cybersecurity Incident at Synnovis in UK
DE000A2TSL71
Cybersecurity Incident at Synnovis in UK SYNLAB AG ("SYNLAB", FSE: SYAB) confirms that Synnovis, a partnership between two London-based hospital Trusts and SYNLAB UK & Ireland, was the victim of a cyber-attack on 3 June 2024. A taskforce of IT experts from Synnovis and the National Health Service in UK (NHS England) is working diligently to fu...
SYNLAB AG
About the publication
31 May 2024 08:40AM
Cinven announces public delisting acquisition offer | Conclusion of Delisting Agreement
DE000A2TSL71
SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed a delisting agreement (“Delisting Agreement”) with Ephios Bidco GmbH, a subsidiary of Ephios Luxembourg S.à r.l., both holding companies controlled by investment funds advised by Cinven Limited. Concurrently, Ephios BidCo GmbH announced its decision to make a public delisting acquisition offer to the...
SYNLAB AG
About the publication
31 May 2024 08:40AM
Cinven announces public delisting acquisition offer | Conclusion of Delisting Agreement
DE000A2TSL71
SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed a delisting agreement (“Delisting Agreement”) with Ephios Bidco GmbH, a subsidiary of Ephios Luxembourg S.à r.l., both holding companies controlled by investment funds advised by Cinven Limited. Concurrently, Ephios BidCo GmbH announced its decision to make a public delisting acquisition offer to the...
SYNLAB AG
About the publication
31 May 2024 08:35AM
SYNLAB AG; Bidder: Ephios Bidco GmbH
DE000A2TSL71
EQS-WpÜG: Ephios Bidco GmbH / Tender Offer Tender Offer / Target company: SYNLAB AG; Bidder: Ephios Bidco GmbH 31.05.2024 / 08:35 CET/CEST Dissemination of an announcement according to the German Securities Acquisition and Takeover Act (WpÜG), transmitted by EQS News - a service of EQS Group AG. The bidder is solely responsible for the c...
Ephios Bidco GmbH
About the publication
08 May 2024 07:00AM
SYNLAB delivers strong performance in Q1 2024
DE000A2TSL71
SYNLAB delivers strong performance in Q1 2024   Revenue at €682 million Strong underlying organic growth at 3.9% (Q1 2023: 10.0%); 5.2% adjusted for working days Adjusted EBITDA at €123 million (increased by 4% compared to Q1 2023) Strong Adjusted EBITDA margin at 18.0% (Q1 2023: 16.9%), at the upper end of the guided range for FY 2024 of 17-1...
SYNLAB AG
About the publication
08 May 2024 07:00AM
SYNLAB delivers strong performance in Q1 2024
DE000A2TSL71
SYNLAB delivers strong performance in Q1 2024   Revenue at €682 million Strong underlying organic growth at 3.9% (Q1 2023: 10.0%); 5.2% adjusted for working days Adjusted EBITDA at €123 million (increased by 4% compared to Q1 2023) Strong Adjusted EBITDA margin at 18.0% (Q1 2023: 16.9%), at the upper end of the guided range for FY 2024 of 17-1...
SYNLAB AG
About the publication
30 April 2024 02:56PM
SYNLAB Italy has restored operations after cyber-attack
DE000A2TSL71
SYNLAB Italy has restored operations after cyber-attack   SYNLAB Italy has restored operations and will gradually resume all services for patients and customers. Due to a cyber-attack, SYNLAB had suspended operations in Italy as a precautionary measure. SYNLAB Group confirms no impact on operations in other countries.   SYNLAB AG ("SYNLAB", FSE...
SYNLAB AG
About the publication
19 April 2024 07:06PM
SYNLAB affected by cyber-attack in Italy
DE000A2TSL71
Disclosure of an inside information according to Article 17 MAR of the Regulation (EU) No 596/2014   SYNLAB affected by cyber-attack in Italy SYNLAB AG ("SYNLAB”, FSE: SYAB) announces that SYNLAB Italy is affected by the consequences of a cyber-attack. As a precaution and in accordance with the SYNLAB IT security procedures, all IT systems in Ita...
SYNLAB AG
About the publication
25 March 2024 07:00AM
SYNLAB delivers robust performance in FY 2023
DE000A2TSL71
Revenue at €2.64 billion Strong underlying organic growth: 6.4% (Q4 2023: 4.9%), well above the mid-term organic growth target Adjusted EBITDA margin at 16.6% (Q4 2023: 17.0%) €40 million of SALIX savings Unlevered free cash flow at €75 million Eight acquisitions completed with an EV of €90 million Active portfolio management strategy impro...
SYNLAB AG
About the publication
25 March 2024 07:00AM
SYNLAB delivers robust performance in FY 2023
DE000A2TSL71
Revenue at €2.64 billion Strong underlying organic growth: 6.4% (Q4 2023: 4.9%), well above the mid-term organic growth target Adjusted EBITDA margin at 16.6% (Q4 2023: 17.0%) €40 million of SALIX savings Unlevered free cash flow at €75 million Eight acquisitions completed with an EV of €90 million Active portfolio management strategy impro...
SYNLAB AG
About the publication
08 November 2023 07:30AM
Continued strong performance in the third quarter of 2023
DE000A2TSL71
SYNLAB AG: Continued strong performance in the third quarter of 2023 Robust 9M 2023 performance with revenue of €2.0 billion Strong underlying organic growth: 6.9% in 9M 2023 (Q3 2023: 5.1%), well above the mid-term organic growth target Adjusted EBITDA margin in 9M 2023 at 16.5% (Q3 2023: 15.6%), in line with the seasonality of the SYNLAB busine...
SYNLAB AG
About the publication
02 November 2023 05:46PM
SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven
DE000A2TSL71
SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven   Management Board and Supervisory Board of SYNLAB AG published their Joint Reasoned Statement, in which they make a neutral statement. The Boards abstain from a recommendation to the SYNLAB Shareholders whether to accept or decline the Offer. The Management Board ...
SYNLAB AG
About the publication
10 October 2023 08:32AM
myEDIT-B
DE000A2TSL71
EQS-Media / 10.10.2023 / 08:32 CET/CEST SYNLAB International GmbH Moosacher Straße 88 80809 Munich Germany Press Release Munich, 10 October 2023 SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B SYNLAB’s myEDIT-B is the world’s first blood-based test for the differential diagnosis betwee...
SYNLAB AG
About the publication
29 September 2023 08:22AM
SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven
DE000A2TSL71
SYNLAB AG Moosacher Str. 88 80809 Munich Germany Press Release   Munich, 29 September 2023 SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven Cinven to launch public acquisition offer to all shareholders at a price of €10.00 per SYNLAB share in cash SYNLAB knows Cinven well as a supportive long-st...
SYNLAB AG
About the publication
29 September 2023 08:17AM
Cinven announces public acquisition offer | Conclusion of Investment Agreement
DE000A2TSL71
SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed an investment agreement (“Investment Agreement”) with Ephios Luxembourg S.à r.l. and its subsidiary Ephios Bidco GmbH, two holding companies controlled by investment funds advised by Cinven Limited. Concurrently, Ephios Luxembourg S.à r.l. announced its decision to make a voluntary public acquisition...
SYNLAB AG
About the publication
29 September 2023 08:09AM
Ephios Luxembourg S.à r.l.
DE000A2TSL71
EQS-WpÜG: Ephios Luxembourg S.à r.l. / Tender Offer Tender Offer / Target company: SYNLAB AG; Bidder: Ephios Luxembourg S.à r.l. 29.09.2023 / 08:09 CET/CEST Dissemination of an announcement according to the German Securities Acquisition and Takeover Act (WpÜG), transmitted by EQS News - a service of EQS Group AG. The bidder ...
Ephios Luxembourg S.à r.l.
About the publication
14 August 2023 07:45AM
SYNLAB agrees to sell its veterinary diagnostics business to Mars
DE000A2TSL71
SYNLAB AG Moosacher Straße 88 80809 Munich Germany Press Release   Munich, 14 August 2023 SYNLAB agrees to sell its veterinary diagnostics business to Mars SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, has agreed to sell its veterinary diagnostics business (SYNLAB VET) to Mars Incorpora...
SYNLAB AG
About the publication
09 August 2023 07:30AM
Continued strong performance in the second quarter of 2023
DE000A2TSL71
SYNLAB AG Moosacher Str. 88 80809 Munich Germany Press Release   Munich, 9 August 2023 SYNLAB AG: Continued strong performance in the second quarter of 2023   Robust H1 2023 performance with revenue of €1.4 billion Strong underlying organic growth: 7.1% in H1 2023 (Q2 2023: 4.4%) Adjusted EBITDA margin in H1 2023 at 16.9% (Q2 2023: 1...
SYNLAB AG
About the publication
17 July 2023 07:30AM
SYNLAB plays key role in the largest ever multinational study on cholesterol
DE000A2TSL71
Munich, 17 July 2023 SYNLAB plays key role in the largest ever multinational study on cholesterol SYNLAB participates in largest ever multi-national study to determine variations in lipid profiles to improve understanding of cardiovascular risk in different countries Significant differences in total cholesterol levels across 17 countries provid...
SYNLAB AG
About the publication
17 July 2023 07:30AM
SYNLAB AG: SYNLAB plays key role in the largest ever multinational study on cholesterol
DE000A2TSL71
Munich, 17 July 2023 SYNLAB plays key role in the largest ever multinational study on cholesterol SYNLAB participates in largest ever multi-national study to determine variations in lipid profiles to improve understanding of cardiovascular risk in different countries Significant differences in total cholesterol levels across 17 countries provid...
SYNLAB AG
About the publication
28 June 2023 07:30AM
SYNLAB AG: SYNLAB invests in innovative Healthcare Centre in Florence
DE000A2TSL71
SYNLAB invests in innovative Healthcare Centre in Florence, strengthening its position as leading diagnostic services provider in Italy   SYNLAB invests €8 million to build a new 4000m2 medical care centre within Florence’s Manifattura Tabacchi The new centre will offer a wide range of routine diagnostics, specialty testing, and medical healthcar...
SYNLAB AG
About the publication
28 June 2023 07:30AM
SYNLAB invests in innovative Healthcare Centre in Florence
DE000A2TSL71
SYNLAB invests in innovative Healthcare Centre in Florence, strengthening its position as leading diagnostic services provider in Italy   SYNLAB invests €8 million to build a new 4000m2 medical care centre within Florence’s Manifattura Tabacchi The new centre will offer a wide range of routine diagnostics, specialty testing, and medical healthcar...
SYNLAB AG
About the publication
27 June 2023 01:00AM
SYNLAB agrees to sell Swiss business to Sonic Healthcare
DE000A2TSL71
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities. “After a careful review of our activities in Switzerland and the developments in the diagnostics sector...
SYNLAB AG
About the publication
27 June 2023 01:00AM
SYNLAB AG: SYNLAB agrees to sell Swiss business to Sonic Healthcare
DE000A2TSL71
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities. “After a careful review of our activities in Switzerland and the developments in the diagnostics sector...
SYNLAB AG
About the publication
10 May 2023 07:30AM
SYNLAB AG: SYNLAB reports strong start to fiscal year 2023
DE000A2TSL71
SYNLAB reports strong start to fiscal year 2023 Revenue stable at €702 million compared to prior quarter Robust underlying organic growth of 10.0%, above the 4% forecast for FY 2023 COVID-19 testing revenue at €26 million vs. €70 million in previous quarter Adjusted EBITDA margin at 16.9%, at mid-point of FY 2023 guidance of 16-18% €10 millio...
SYNLAB AG
About the publication
10 May 2023 07:30AM
SYNLAB reports strong start to fiscal year 2023
DE000A2TSL71
SYNLAB reports strong start to fiscal year 2023 Revenue stable at €702 million compared to prior quarter Robust underlying organic growth of 10.0%, above the 4% forecast for FY 2023 COVID-19 testing revenue at €26 million vs. €70 million in previous quarter Adjusted EBITDA margin at 16.9%, at mid-point of FY 2023 guidance of 16-18% €10 millio...
SYNLAB AG
About the publication
09 May 2023 08:00AM
SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region
DE000A2TSL71
SYNLAB Holding Deutschland GmbH Gubener Straße 39 86156 Augsburg Germany Press Release   SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region SYNLAB moves to new city centre location at Schwanthalerhöhe in Munich, increases laboratory space to 6,000 square metres and modernises ...
SYNLAB AG
About the publication
09 May 2023 08:00AM
SYNLAB AG: SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region
DE000A2TSL71
SYNLAB Holding Deutschland GmbH Gubener Straße 39 86156 Augsburg Germany Press Release   SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region SYNLAB moves to new city centre location at Schwanthalerhöhe in Munich, increases laboratory space to 6,000 square metres and modernises ...
SYNLAB AG
About the publication
16 March 2023 07:00AM
SYNLAB delivers robust underlying growth in FY 2022
DE000A2TSL71
SYNLAB delivers robust underlying growth in FY 2022   Revenue at €3.25 billion exceeds the initial 2022 guidance Robust underlying organic growth of 6.2% outperforms the guidance of 3%+ COVID-19 testing revenue at €790 million with gradual reductions in price and volume Adjusted EBITDA of €753 million and margin at 23.2% 23 acquisitions at €...
SYNLAB AG
About the publication
16 March 2023 07:00AM
SYNLAB AG: SYNLAB delivers robust underlying growth in FY 2022
DE000A2TSL71
SYNLAB delivers robust underlying growth in FY 2022   Revenue at €3.25 billion exceeds the initial 2022 guidance Robust underlying organic growth of 6.2% outperforms the guidance of 3%+ COVID-19 testing revenue at €790 million with gradual reductions in price and volume Adjusted EBITDA of €753 million and margin at 23.2% 23 acquisitions at €...
SYNLAB AG
About the publication
15 March 2023 06:05PM
Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO
DE000A2TSL71
Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO Munich, 15 March 2023 – The Supervisory Board of SYNLAB AG (SYNLAB, FSE: SYAB) today announces that the appointment of Mathieu Floreani as Chief Executive Officer (CEO) of the SYNLAB Group has been extended until the end of 30 April 2028 and the appointment of Sami Bad...
SYNLAB AG
About the publication
15 March 2023 06:05PM
SYNLAB AG: Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO
DE000A2TSL71
Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO Munich, 15 March 2023 – The Supervisory Board of SYNLAB AG (SYNLAB, FSE: SYAB) today announces that the appointment of Mathieu Floreani as Chief Executive Officer (CEO) of the SYNLAB Group has been extended until the end of 30 April 2028 and the appointment of Sami Bad...
SYNLAB AG
About the publication
13 March 2023 12:06PM
SYNLAB AG: Non-binding expression of interest by Cinven for acquisition offer at an indicative offer price of 10.00 Euro per SYNLAB share
DE000A2TSL71
SYNLAB AG (SYNLAB, FSE: SYAB) confirms that funds advised by Cinven Limited have submitted a legally non-binding expression of interest to acquire up to 100% of the Company's shares at an indicative offer price of 10.00 Euro per SYNLAB share. Cinven already holds approximately 43% of the Company's share capital. In the best interests of the Company...
SYNLAB AG
About the publication
13 March 2023 12:06PM
Non-binding expression of interest by Cinven for acquisition offer at an indicative offer price of 10.00 Euro per SYNLAB share
DE000A2TSL71
SYNLAB AG (SYNLAB, FSE: SYAB) confirms that funds advised by Cinven Limited have submitted a legally non-binding expression of interest to acquire up to 100% of the Company's shares at an indicative offer price of 10.00 Euro per SYNLAB share. Cinven already holds approximately 43% of the Company's share capital. In the best interests of the Company...
SYNLAB AG
About the publication
06 February 2023 08:40PM
SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing
DE000A2TSL71
  FY 2022 revenue anticipated to be around €3.25 billion, above guided amount of €3.2 billion Expected strong underlying organic growth of around 6% (above 4% excluding the South-East London hospital outsourcing contract) FY 2022 adjusted EBITDA margin anticipated to be around 23%, slightly below FY 2022 guidance, due to Q4 2022 one-off costs p...
SYNLAB AG
About the publication
06 February 2023 08:40PM
SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing
DE000A2TSL71
  FY 2022 revenue anticipated to be around €3.25 billion, above guided amount of €3.2 billion Expected strong underlying organic growth of around 6% (above 4% excluding the South-East London hospital outsourcing contract) FY 2022 adjusted EBITDA margin anticipated to be around 23%, slightly below FY 2022 guidance, due to Q4 2022 one-off costs p...
SYNLAB AG
About the publication
06 February 2023 08:36PM
SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes
DE000A2TSL71
SYNLAB AG (SYNLAB, FSE: SYAB) is experiencing a reduced level of COVID-19 testing volume and dropping COVID-19 PCR prices in some of its key markets in January 2023. This leads SYNLAB to update its FY 2023 guidance despite anticipated continued growing underlying business and the focus to recover pre-pandemic productivity. For 2023, SYNLAB now expe...
SYNLAB AG
About the publication
06 February 2023 08:36PM
SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes
DE000A2TSL71
SYNLAB AG (SYNLAB, FSE: SYAB) is experiencing a reduced level of COVID-19 testing volume and dropping COVID-19 PCR prices in some of its key markets in January 2023. This leads SYNLAB to update its FY 2023 guidance despite anticipated continued growing underlying business and the focus to recover pre-pandemic productivity. For 2023, SYNLAB now expe...
SYNLAB AG
About the publication
04 January 2023 07:05PM
Portuguese competition authority investigating the local laboratory diagnostics market – SYNLAB’s operations in Portugal included in such investigation
DE000A2TSL71
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and speciality testing in Europe, has announced today that the Portuguese competition authority Autoridade da Concorrência (“AdC”) initiated proceedings against several medical diagnostic providers active in Portugal, including SYNLAB. The AdC has assessed that two Portuguese subsidiari...
SYNLAB AG
About the publication
04 January 2023 06:58PM
Proceedings of the Portuguese Competition Authority against entities of SYNLAB
DE000A2TSL71
SYNLAB AG announces that the Portuguese Competition Authority (Autoridade da Concorrência) has initiated proceedings against, inter alia, two Portuguese entities of SYNLAB Group (“SYNLAB”) and has associated SYNLAB AG with the proceedings regarding potential violations of competition law in Portugal. The Portuguese Competition Authority has formall...
SYNLAB AG
About the publication
10 November 2022 07:00AM
SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance
DE000A2TSL71
SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance Robust 9M 2022 performance with revenue of €2.5 billion Strong underlying organic growth (excluding COVID-19 related revenues): +6.3% in 9M 2022 and +4.1% in Q3 2022, well above our mid-term organic growth target COVID-19 testing revenue €72...
SYNLAB AG
About the publication
10 November 2022 07:00AM
SYNLAB AG: SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance
DE000A2TSL71
SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance Robust 9M 2022 performance with revenue of €2.5 billion Strong underlying organic growth (excluding COVID-19 related revenues): +6.3% in 9M 2022 and +4.1% in Q3 2022, well above our mid-term organic growth target COVID-19 testing revenue €72...
SYNLAB AG
About the publication
27 October 2022 09:18AM
SYNLAB AG: SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
DE000A2TSL71
SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microba’s leading researchers in the field of microbiome analysis. The combination of leading-edge ...
SYNLAB AG
About the publication
27 October 2022 09:18AM
SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
DE000A2TSL71
SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microba’s leading researchers in the field of microbiome analysis. The combination of leading-edge ...
SYNLAB AG
About the publication
11 August 2022 07:00AM
SYNLAB reports solid H1 2022 results and raises 2022 revenue guidance
DE000A2TSL71
  Robust H1 2022 performance with revenue of €1.85 billion Strong underlying organic growth (excluding COVID-19 related revenues): +7.2% in H1 2022 and +4.0% in Q2 2022 Higher than expected COVID-19 testing revenue: €618 million in H1 2022 (€164 million in Q2 2022) Ten bolt-on and specialty acquisitions completed in H1 2022 in seven countries (...
SYNLAB AG
About the publication
More SYNLAB AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 2 4th October 2023 Ebsworth GmbH DD
Short Seller (DE) 1 20th December 2021 PSquared Asset Management AG SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN